Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma Journal Article
| Authors: | Hutson, T. E.; Bukowski, R. M.; Rini, B. I.; Gore, M. E.; Larkin, J. M.; Figlin, R. A.; Barrios, C. H.; Escudier, B.; Lin, X.; Fly, K.; Martell, B.; Matczak, E.; Motzer, R. J. |
| Article Title: | Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma |
| Abstract: | Background:We retrospectively analyzed sunitinib outcome as a function of age in metastatic renal cell carcinoma (mRCC) patients.Methods:Data were pooled from 1059 patients in six trials. Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) were compared by log-rank test between patients aged <70 (n=857; 81%) and ≥70 (n=202; 19%) years.Results:In first-line patients, median PFS was comparable in younger and older patients, 9.9 vs 11.0 months, respectively (HR, 0.89; 95% CI: 0.73-1.09; P=0.2629), as was median OS, 23.6 vs 25.6 months (HR, 0.93; 95% CI: 0.74-1.18; P=0.5442). Similarly, in cytokine-refractory patients, median PFS was 8.1 vs 8.4 months (HR, 0.79; 95% CI: 0.49-1.28; P=0.3350), while median OS was 20.2 vs 15.8 months (HR, 1.14; 95% CI: 0.73-1.79; P=0.5657). Some treatment-emergent adverse events were significantly less common in younger vs older patients, including fatigue (60% vs 69%), cough (20% vs 29%), peripheral edema (17% vs 27%), anemia (18% vs 25%), decreased appetite (13% vs 29%), and thrombocytopenia (16% vs 25%; all P<0.05). Hand-foot syndrome was more common in younger patients (32% vs 24%).Conclusions:Advanced age should not be a deterrent to sunitinib therapy and elderly patients may achieve additional clinical benefit. © 2014 Cancer Research UK. |
| Keywords: | adult; treatment outcome; aged; aged, 80 and over; disease-free survival; middle aged; retrospective studies; young adult; major clinical study; overall survival; constipation; fatigue; neutropenia; sunitinib; diarrhea; drug efficacy; drug safety; hypertension; prospective studies; anorexia; progression free survival; multiple cycle treatment; pain; anemia; nausea; stomatitis; thrombocytopenia; vomiting; dehydration; myalgia; weight reduction; randomized controlled trials as topic; renal cell carcinoma; kidney neoplasms; age; abdominal pain; arthralgia; asthenia; backache; chill; coughing; dizziness; dyspnea; fever; rash; insomnia; depression; thorax pain; carcinoma, renal cell; clinical trials, phase iii as topic; urinary tract infection; peripheral edema; xerostomia; erythema; skin discoloration; headache; kaplan meier method; hypothyroidism; gastroesophageal reflux; indoles; pyrroles; dyspepsia; flatulence; hand foot syndrome; dry skin; alopecia; epistaxis; kidney metastasis; geriatric patient; metastatic; mouth pain; dysgeusia; retrospective analysis; decreased appetite; very elderly; humans; human; male; female; priority journal; article |
| Journal Title: | British Journal of Cancer |
| Volume: | 110 |
| Issue: | 5 |
| ISSN: | 0007-0920 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2014-03-01 |
| Start Page: | 1125 |
| End Page: | 1132 |
| Language: | English |
| DOI: | 10.1038/bjc.2013.832 |
| PUBMED: | 24434434 |
| PROVIDER: | scopus |
| PMCID: | PMC3950861 |
| DOI/URL: | |
| Notes: | Export Date: 1 August 2014 -- CODEN: BJCAA -- Source: Scopus |
